1. Comparisons between tumor burden and other prognostic factors that influence survival of patients with non‐small cell lung cancer treated with immune checkpoint inhibitors. Issue 12 (3rd November 2019) Authors: Sakata, Yoshihiko; Kawamura, Kodai; Ichikado, Kazuya; Shingu, Naoki; Yasuda, Yuko; Eguchi, Yoshitomo; Hisanaga, Jumpei; Nitawaki, Tatsuya; Iio, Miwa; Sekido, Yuko; Nakano, Aiko; Sakagami, Takuro Journal: Thoracic cancer Issue: Volume 10:Issue 12(2019) Page Start: 2259 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer. (September 2016) Authors: Sakata, Yoshihiko; Kawamura, Kodai; Shingu, Naoki; Ichikado, Kazuya Journal: Lung cancer Issue: Volume 99(2016) Page Start: 120 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Histologic transformation of epidermal growth factor receptor–mutated lung cancer. (May 2022) Authors: Fujimoto, Daichi; Akamatsu, Hiroaki; Morimoto, Takeshi; Wakuda, Kazushige; Sato, Yuki; Kawa, Yoshitaka; Yokoyama, Toshihide; Tamiya, Motohiro; Hiraoka, Ryota; Shingu, Naoki; Ikeda, Hideki; Tamiya, Akihiro; Kanazu, Masaki; Miyauchi, Eisaku; Miura, Satoru; Yanai, Masaaki; Yomota, Makiko; Morinaga, ... Journal: European journal of cancer Issue: Volume 166(2022) Page Start: 41 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003). Issue 1 (15th November 2022) Authors: Ishii, Hidenobu; Azuma, Koichi; Shimose, Takayuki; Yoshioka, Hiroshige; Kurata, Takayasu; Shingu, Naoki; Okamoto, Masaki; Kawashima, Yosuke; Okamoto, Isamu Journal: Thoracic cancer Issue: Volume 14:Issue 1(2023) Page Start: 105 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment. (April 2019) Authors: Sakata, Yoshihiko; Kawamura, Kodai; Ichikado, Kazuya; Shingu, Naoki; Yasuda, Yuko; Eguchi, Yoshitomo; Anan, Keisuke; Hisanaga, Junpei; Nitawaki, Tatsuya; Iio, Miwa; Sekido, Yuko; Nakano, Aiko; Sakagami, Takuro Journal: Lung cancer Issue: Volume 130(2019) Page Start: 159 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. The effects of switching EGFR‐TKI treatments for non‐small cell lung cancer because of adverse events. Issue 2 (2nd December 2018) Authors: Sakata, Yoshihiko; Kawamura, Kodai; Shingu, Naoki; Hiroshige, Shigeo; Yasuda, Yuko; Eguchi, Yoshitomo; Anan, Keisuke; Hisanaga, Junpei; Nitawaki, Tatsuya; Nakano, Aiko; Ichikado, Kazuya Journal: Asia-Pacific journal of clinical oncology Issue: Volume 16:Issue 2(2020) Page Start: e113 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗